David Smith
Psychiatry · Sacramento, CANPI 1114902178
Payments from drug & device makers
Across 795 payments — averaging $740.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$370K
- Neurocrine Biosciences, Inc.$118K
- Johnson & Johnson$70K
- Axsome Therapeutics, Inc.$26K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$462
- plus $607 from 6 others
What the payments were for
- Consulting fees$71,19212%
- Speaking & faculty fees$460,05178%
- Travel & lodging$42,7207%
- Food & beverage$13,9562%
- Education$4200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 470 | $370,139 |
| Neurocrine Biosciences, Inc. | 109 | $118,350 |
| Johnson & Johnson | 125 | $70,029 |
| Axsome Therapeutics, Inc. | 26 | $26,266 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 11 | $2,485 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 19 | $462 |
| AbbVie(2 entities) | 24 | $330 |
| Indivior Inc. | 6 | $125 |
| Tris Pharma Inc | 1 | $59 |
| Alkermes, Inc. | 2 | $44 |
| Almatica Pharma LLC | 1 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$217,295
- ABILIFY MAINTENA$150,098
- INGREZZA$116,881
- SPRAVATO$68,048
- ABILIFY ASIMTUFII$33,106
- Auvelity$25,717
How this compares
$588,338 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SpravatoEsketamine Hcl | 85 | $123,927 |
| RexultiBrexpiprazole | 14 | $36,170 |
| VraylarCariprazine Hcl | 26 | $31,853 |
| AustedoDeutetrabenazine | 11 | $24,225 |
| CaplytaLumateperone Tosylate | 13 | $23,310 |
| AuvelityDextromethorphan Hbr/Bupropion | 17 | $14,326 |
| Chlorpromazine Hcl | 13 | $4,374 |
| Buprenorphine Hcl | 25 | $1,669 |
| Ziprasidone Hcl | 12 | $1,029 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 13 | $959 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 26 | $721 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 13 | $461 |
| Quetiapine Fumarate | 42 | $421 |
| Doxepin Hcl | 23 | $341 |
| Aripiprazole | 20 | $265 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSpravato | $70,029 | $123,92785 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $370,139 | $36,17014 claims |
| AbbVieVraylar | $330 | $31,85326 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $462 | $23,31013 claims |
| Axsome Therapeutics, Inc.Auvelity | $26,266 | $14,32617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Sacramento
- Susan SmigaSacramento$1.7M
- Elly LeeIrvine$49.8M
- Daniel ChuehOrange$17.9M
- Eric ChavezSan Diego$15.5M
- Lara ShirikjianTorrance$12.6M
- John DuffySanta Ana$12M
- Marina BusselPlaya Vista$12M
- Sherry SoefjeOceanside$11.9M
- Steven MacinaHuntington Beach$11.1M
- Wakelin McNeelRosemead$11M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.